These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 2758725)

  • 1. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.
    Lennard L; Van Loon JA; Weinshilboum RM
    Clin Pharmacol Ther; 1989 Aug; 46(2):149-54. PubMed ID: 2758725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation.
    Schütz E; Gummert J; Armstrong VW; Mohr FW; Oellerich M
    Eur J Clin Chem Clin Biochem; 1996 Mar; 34(3):199-205. PubMed ID: 8721407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.
    Lennard L; Van Loon JA; Lilleyman JS; Weinshilboum RM
    Clin Pharmacol Ther; 1987 Jan; 41(1):18-25. PubMed ID: 3467886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells.
    Bergan S; Rugstad HE; Klemetsdal B; Giverhaug T; Bentdal O; Sødal G; Hartmann A; Aarbakke J; Stokke O
    Ther Drug Monit; 1997 Jun; 19(3):318-26. PubMed ID: 9200774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.
    Dervieux T; Médard Y; Baudouin V; Maisin A; Zhang D; Broly F; Loirat C; Jacqz-Aigrain E
    Br J Clin Pharmacol; 1999 Dec; 48(6):793-800. PubMed ID: 10594482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
    Schedel J; Gödde A; Schütz E; Bongartz TA; Lang B; Schölmerich J; Müller-Ladner U
    Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
    Lennard L; Lilleyman JS
    Ther Drug Monit; 1996 Aug; 18(4):328-34. PubMed ID: 8857546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases.
    Chapdelaine A; Mansour AM; Troyanov Y; Williamson DR; Doré M
    Clin Rheumatol; 2017 Jun; 36(6):1341-1348. PubMed ID: 28130685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.
    Chouchana L; Narjoz C; Roche D; Golmard JL; Pineau B; Chatellier G; Beaune P; Loriot MA
    Pharmacogenomics; 2014 Apr; 15(6):745-57. PubMed ID: 24897283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population.
    Hindorf U; Peterson C; Almer S
    Ther Drug Monit; 2004 Dec; 26(6):673-8. PubMed ID: 15570193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
    Reinshagen M; Schütz E; Armstrong VW; Behrens C; von Tirpitz C; Stallmach A; Herfarth H; Stein J; Bias P; Adler G; Shipkova M; Kruis W; Oellerich M; von Ahsen N
    Clin Chem; 2007 Jul; 53(7):1306-14. PubMed ID: 17495015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
    Lee MN; Kang B; Choi SY; Kim MJ; Woo SY; Kim JW; Choe YH; Lee SY
    Inflamm Bowel Dis; 2015 Dec; 21(12):2897-908. PubMed ID: 26332308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
    Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
    Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.